Do they need money?
The small-cap trader’s #1 question. We read a company’s cash on hand vs. its cash burn straight from SEC filings and answer yes or no — is a dilutive raise coming? Enter a ticker.
Reading APUS’s cash-flow filings…
APUS · Apimeds Pharmaceuticals US, Inc. · from SEC EDGAR
YES
Going-concern warning
auditor flagged substantial doubt
Apimeds Pharmaceuticals US, Inc. disclosed substantial doubt about its ability to continue as a going concern — management typically has to raise capital to keep operating. Dilution risk is high.
Cash & short-term investmentsas of $2.5M
Operating cash flow (annual)-$8.9M
Net income (annual)-$6.0M
Estimated runway~3 months
Going-concern warning⚠ Flagged
Shelf on file? (can they dilute)Check →
Last offering? (have they diluted)Check →
Runway = cash ÷ operating burn, from SEC XBRL. Filings lag 40–90 days, so figures are as filed — a raise may already have happened. Educational, not investment advice; verify against the filings. Latest filing ↗